Cancer Therapy-Associated Thrombosis

Overview

Journal Arterioscler Thromb Vasc Biol

Date 2021 Feb 11

PMID 33567864

Citations 50

Authors

Steven P Grover

Yohei M Hisada

Raj S Kasthuri

Brandi N Reeves

Nigel Mackman

Affiliations

Soon will be listed here.

Abstract

[Figure: see text].

Citing Articles

A meta-analysis on the impact of concurrent or pre-existing cancer diagnosis on acute myocardial infarction outcomes.

Wang J, Yu J PLoS One. 2025; 20(1):e0318437.

PMID: 39888923 PMC: 11785289. DOI: 10.1371/journal.pone.0318437.

Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies.

Vladic N, Englisch C, Ay C, Pabinger I Res Pract Thromb Haemost. 2025; 9(1):102664.

PMID: 39877524 PMC: 11772966. DOI: 10.1016/j.rpth.2024.102664.

Assessment of Hypercoagulability in Splanchnic Vein Thrombosis by Measurement of the Hemostasis Enzymes Thrombin and Activated Protein C.

Reda S, Chang J, Busse J, Schwarz N, McRae H, Muller J Int J Mol Sci. 2025; 26(1.

PMID: 39796151 PMC: 11719462. DOI: 10.3390/ijms26010292.

Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications.

Li K, Guo B, Gu J, Ta N, Gu J, Yu H Mater Today Bio. 2025; 30:101375.

PMID: 39759851 PMC: 11699619. DOI: 10.1016/j.mtbio.2024.101375.

Deep Vein Thrombosis as a Complication of Gemcitabine-Capecitabine Chemotherapy in Adenocarcinoma of Gallbladder.

Widiasi E, Zaky Romadhon P, Ashariati A, Bintoro S, Noor Diansyah M, Ayu Amrita P J Blood Med. 2024; 15:523-531.

PMID: 39717674 PMC: 11665135. DOI: 10.2147/JBM.S482753.

References

Dunkley S, Gaudry L . Thalidomide causes platelet activation, which can be abrogated by aspirin. J Thromb Haemost. 2007; 5(6):1323-5. DOI: 10.1111/j.1538-7836.2007.02542.x. View

Alias S, Redwan B, Panzenboeck A, Winter M, Schubert U, Voswinckel R . Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2014; 34(4):810-819. PMC: 4728746. DOI: 10.1161/ATVBAHA.113.302991. View

Nalluri S, Chu D, Keresztes R, Zhu X, Wu S . Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008; 300(19):2277-85. DOI: 10.1001/jama.2008.656. View

Kasthuri R, Hisada Y, Ilich A, Key N, Mackman N . Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer. Res Pract Thromb Haemost. 2020; 4(4):636-643. PMC: 7292676. DOI: 10.1002/rth2.12317. View

Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y . Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood. 2019; 133(14):1597-1606. PMC: 6450432. DOI: 10.1182/blood-2018-10-881557. View

Grilz E, Konigsbrugge O, Posch F, Schmidinger M, Pirker R, Lang I . Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica. 2018; 103(9):1549-1556. PMC: 6119137. DOI: 10.3324/haematol.2018.192419. View

Nevasaari K, Heikkinen M, TASKINEN P . Tamoxifen and thrombosis. Lancet. 1978; 2(8096):946-7. DOI: 10.1016/s0140-6736(78)91668-9. View

Focaccetti C, Bruno A, Magnani E, Bartolini D, Principi E, Dallaglio K . Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS One. 2015; 10(2):e0115686. PMC: 4324934. DOI: 10.1371/journal.pone.0115686. View

Canale M, Bisceglia I, Lestuzzi C, Parrini I . Arterial Thrombosis in Cancer: Spotlight on the Neglected Vessels. Anticancer Res. 2019; 39(9):4619-4625. DOI: 10.21873/anticanres.13642. View

10.

Wheeler H, Geczy C . Induction of macrophage procoagulant expression by cisplatin, daunorubicin and doxorubicin. Int J Cancer. 1990; 46(4):626-32. DOI: 10.1002/ijc.2910460413. View

11.

Conard J, Cazenave B, Maury J, Horellou M, Samama M . L-asparaginase, antithrombin III, and thrombosis. Lancet. 1980; 1(8177):1091. DOI: 10.1016/s0140-6736(80)91538-x. View

12.

Chang Y, Lee J, Chen W, Chou D, Huang S, Sheu J . A novel role for tamoxifen in the inhibition of human platelets. Transl Res. 2011; 157(2):81-91. DOI: 10.1016/j.trsl.2010.10.004. View

13.

Choueiri T, Schutz F, Je Y, Rosenberg J, Bellmunt J . Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010; 28(13):2280-5. DOI: 10.1200/JCO.2009.27.2757. View

14.

El Accaoui R, Shamseddeen W, Taher A . Thalidomide and thrombosis. A meta-analysis. Thromb Haemost. 2007; 97(6):1031-6. View

15.

Qi W, Min D, Shen Z, Sun Y, Lin F, Tang L . Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer. 2012; 132(12):2967-74. DOI: 10.1002/ijc.27979. View

16.

Vitseva O, Flockhart D, Jin Y, Varghese S, Freedman J . The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates. J Pharmacol Exp Ther. 2004; 312(3):1144-50. DOI: 10.1124/jpet.104.076315. View

17.

Kinhult S, Albertsson M, Eskilsson J, Cwikiel M . Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation. Scanning. 2001; 23(1):1-8. DOI: 10.1002/sca.4950230101. View

18.

Altieri P, Murialdo R, Barisione C, Lazzarini E, Garibaldi S, Fabbi P . 5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1. Br J Pharmacol. 2017; 174(21):3713-3726. PMC: 5647192. DOI: 10.1111/bph.13725. View

19.

Nayak M, Singh S, Roy A, Prakash V, Kumar A, Dash D . Anti-thrombotic effects of selective estrogen receptor modulator tamoxifen. Thromb Haemost. 2011; 106(4):624-35. DOI: 10.1160/TH11-03-0178. View

20.

Xu H, Zong H, Ma C, Ming X, Shang M, Li K . Epidermal growth factor receptor in glioblastoma. Oncol Lett. 2017; 14(1):512-516. PMC: 5494611. DOI: 10.3892/ol.2017.6221. View